IT1247150B - Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli. - Google Patents

Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Info

Publication number
IT1247150B
IT1247150B ITPD910013A ITPD910013A IT1247150B IT 1247150 B IT1247150 B IT 1247150B IT PD910013 A ITPD910013 A IT PD910013A IT PD910013 A ITPD910013 A IT PD910013A IT 1247150 B IT1247150 B IT 1247150B
Authority
IT
Italy
Prior art keywords
cntf
purification
synthesis
escherichia coli
factor
Prior art date
Application number
ITPD910013A
Other languages
English (en)
Inventor
Valle Francesco Della
Lanfranco Callegaro
Alessandro Negro
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Priority to ITPD910013A priority Critical patent/IT1247150B/it
Publication of ITPD910013A0 publication Critical patent/ITPD910013A0/it
Priority to AU11656/92A priority patent/AU1165692A/en
Priority to PCT/EP1992/000122 priority patent/WO1992013072A2/en
Priority to EP92902811A priority patent/EP0566630A1/en
Publication of ITPD910013A1 publication Critical patent/ITPD910013A1/it
Application granted granted Critical
Publication of IT1247150B publication Critical patent/IT1247150B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invenzione si riferisce ad un processo per la sintesi e purificazione del fattore neuronotrofico ciliare umano (CNTF) da Escherichia coli mediante applicazione delle tecnologie del DNA ricombinante. In questo modo si possono ottenere quantità significative di proteina omogenea, tali da iniziare e condurre esperimenti in test clinici anche in associazione ad altre molecole o loro derivati.
ITPD910013A 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli. IT1247150B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITPD910013A IT1247150B (it) 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
AU11656/92A AU1165692A (en) 1991-01-21 1992-01-21 Process for the synthesis and purification of human ciliary neuronotrophic factor (cntf) from escherichia coli
PCT/EP1992/000122 WO1992013072A2 (en) 1991-01-21 1992-01-21 Process for the synthesis and purification of human ciliary neuronotrophic factor (cntf) from escherichia coli
EP92902811A EP0566630A1 (en) 1991-01-21 1992-01-21 Process for the synthesis and purification of human ciliary neuronotrophic factor (cntf) from escherichia coli

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITPD910013A IT1247150B (it) 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Publications (3)

Publication Number Publication Date
ITPD910013A0 ITPD910013A0 (it) 1991-01-21
ITPD910013A1 ITPD910013A1 (it) 1992-07-21
IT1247150B true IT1247150B (it) 1994-12-12

Family

ID=11389421

Family Applications (1)

Application Number Title Priority Date Filing Date
ITPD910013A IT1247150B (it) 1991-01-21 1991-01-21 Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Country Status (4)

Country Link
EP (1) EP0566630A1 (it)
AU (1) AU1165692A (it)
IT (1) IT1247150B (it)
WO (1) WO1992013072A2 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98304A (en) * 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
KR910016921A (ko) * 1990-03-14 1991-11-05 파디아 에스. 피. 에이 인간의 모양체 신경원영양 인자, 그를 코딩하는 dna 서열 및 재조합 기술에 의한 그의 제조방법

Also Published As

Publication number Publication date
ITPD910013A1 (it) 1992-07-21
AU1165692A (en) 1992-08-27
WO1992013072A3 (en) 1992-09-17
WO1992013072A2 (en) 1992-08-06
EP0566630A1 (en) 1993-10-27
ITPD910013A0 (it) 1991-01-21

Similar Documents

Publication Publication Date Title
FI103506B1 (fi) Menetelmä syklisten aminohappojohdannaisten valmistamiseksi ja menetelmässä käytettävä välituote
PT96068A (pt) Processo para a producao de proteina biologicamente activa
PT88385A (pt) Process for preparing conjugates of citokines with immunoglobulins
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
BR9406814A (pt) Concentrado de imunoglobulinas g de uso terapêutico e processo de produção do referido concentrado
PT730608E (pt) Composicoes compreendendo hidratos de carbono e proeinas relacionadas pelo complemento e metodos para produzir e utilizar as referidas composicoes
DK0662827T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
BG101118A (en) Therapeutical compounds
GR3006073T3 (it)
DK0500773T3 (da) Ikke-glycosyleret FGF-4 og præparater indeholdende dette
BR0013638A (pt) Novas moléculas semelhantes a interferon beta
DE69233311D1 (de) Weidelgraspollen-allergen
IT1247150B (it) Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
HUT57708A (en) Process for producing non ionic carboxamide derivative contrast materials
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69331479D1 (de) Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen
Liebl et al. Serotonin‐activated α2‐macroglobulin inhibits neurite outgrowth and survival of embryonic sensory and cerebral cortical neurons
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
ITRM920603A0 (it) La sequenza dell'inserto cprl3, parte del gene della proteina della oociste di cryptosporidium (cowp), e derivati utili per la diagnosi dell'infezione da cryptosporidium
ATE229813T1 (de) Verfahren und testsätze mit makrophagen stimulierenden proteinen
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
FR2416688A1 (fr) Tuteur miniaturise a bagues, ameliore et a faible encombrement pour la chirurgie de la main
ATE106874T1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960126